Alkem Laboratories Limited

NSE ALKEM.NS

Alkem Laboratories Limited Dividend Yield on January 14, 2025: 0.90%

Alkem Laboratories Limited Dividend Yield is 0.90% on January 14, 2025, a 1.81% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • Alkem Laboratories Limited 52-week high Dividend Yield is 0.97% on April 19, 2024, which is 7.98% above the current Dividend Yield.
  • Alkem Laboratories Limited 52-week low Dividend Yield is 0.71% on September 13, 2024, which is -21.18% below the current Dividend Yield.
  • Alkem Laboratories Limited average Dividend Yield for the last 52 weeks is 0.84%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
Loading...
NSE: ALKEM.NS

Alkem Laboratories Limited

CEO Dr. Vikas Gupta
IPO Date Dec. 23, 2015
Location India
Headquarters Devashish Building
Employees 17,432
Sector Health Care
Industries
Description

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Similar companies

AJANTPHARM.NS

Ajanta Pharma Limited

USD 32.53

1.58%

IPCALAB.NS

Ipca Laboratories Limited

USD 18.35

0.69%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.58

0.68%

ABBOTINDIA.NS

Abbott India Limited

USD 326.23

-0.98%

APLLTD.NS

Alembic Pharmaceuticals Limited

USD 11.66

0.86%

StockViz Staff

January 15, 2025

Any question? Send us an email